Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 2
2007 2
2008 1
2011 1
2014 3
2015 2
2016 1
2020 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3).
Yamani A, Zdżalik-Bielecka D, Lipner J, Stańczak A, Piórkowska N, Stańczak PS, Olejkowska P, Hucz-Kalitowska J, Magdycz M, Dzwonek K, Dubiel K, Lamparska-Przybysz M, Popiel D, Pieczykolan J, Wieczorek M. Yamani A, et al. Among authors: lamparska przybysz m. Eur J Med Chem. 2021 Jan 15;210:112990. doi: 10.1016/j.ejmech.2020.112990. Epub 2020 Nov 7. Eur J Med Chem. 2021. PMID: 33199155 Review.
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I-Indole Derivatives.
Stypik M, Zagozda M, Michałek S, Dymek B, Zdżalik-Bielecka D, Dziachan M, Orłowska N, Gunerka P, Turowski P, Hucz-Kalitowska J, Stańczak A, Stańczak P, Mulewski K, Smuga D, Stefaniak F, Gurba-Bryśkiewicz L, Leniak A, Ochal Z, Mach M, Dzwonek K, Lamparska-Przybysz M, Dubiel K, Wieczorek M. Stypik M, et al. Among authors: lamparska przybysz m. Pharmaceuticals (Basel). 2022 Jul 30;15(8):949. doi: 10.3390/ph15080949. Pharmaceuticals (Basel). 2022. PMID: 36015098 Free PMC article.
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.
Popiel D, Stańczak A, Skupińska M, Mikołajczyk A, Stańczak P, Mituła F, Hucz-Kalitowska J, Jastrzębska K, Smuga D, Dominowski J, Delis M, Mulewski K, Pietruś W, Zdżalik-Bielecka D, Dzwonek K, Lamparska-Przybysz M, Yamani A, Olejkowska P, Piórkowska N, Dubiel K, Wieczorek M, Pieczykolan J. Popiel D, et al. Among authors: lamparska przybysz m. Front Oncol. 2024 Jan 12;13:1293728. doi: 10.3389/fonc.2023.1293728. eCollection 2023. Front Oncol. 2024. PMID: 38282676 Free PMC article.
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K. Zdzalik D, et al. Among authors: lamparska przybysz m. J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98. doi: 10.1007/s00432-014-1589-3. Epub 2014 Feb 8. J Cancer Res Clin Oncol. 2014. PMID: 24509625 Free PMC article.
16 results